We then stratified EGFR-mutant NSCLC patients by PLK1 mRNA expression (sorted from high to low), defining those with expression above the median as the PLK1-high group and those below as the PLK1-low group. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.